Latest

10:47
[ CSOP SK Hynix Daily (2x) Leveraged Product (07709.HK) Rose 18.57% in Morning Trade, AUM at HKD 51.756 Billion ] NewTimeSpace News: As of 10:42 on July 20, CSOP SK Hynix Daily (2x) Leveraged Product (07709.HK) advanced 18.57%, with the latest price at HKD 53.120.
Tag： 07709.HKCSOP SK Hynix Daily (2x) Leveraged ProductETF
10:47
[ Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) Rose 20.92% in Morning Trade, Turnover at HKD 1.194 Billion ] NewTimeSpace News: As of 10:44 on July 20, Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) advanced 20.92%, with the latest price at HKD 81.260.
Tag： Csop Samsung Electronics Daily (-2x) Inverse ProductETF07347.HK
10:37
[ Ishares Ftse China A50 Etf (02823.HK) Rose 2.07% in Morning Trade, Turnover at HKD 77.2013 Million ] NewTimeSpace News: As of 10:34 on July 20, Ishares Ftse China A50 Etf (02823.HK) advanced 2.07%, with the latest price at HKD 16.740.
Tag： 02823.HKETFIshares Ftse China A50 Etf
10:35
[ CSOP Hang Seng Biotech ETF (03174.HK) Rose 3.75% in Morning Trade, AUM at HKD 827 Million ] NewTimeSpace News: As of 10:32 on July 20, CSOP Hang Seng Biotech ETF (03174.HK) advanced 3.75%, with the latest price at HKD 3.372.
Tag： 03174.HKCSOP Hang Seng Biotech ETFETF
10:32
[ Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) Rose 3.36% in Morning Trade, Turnover at HKD 26.0303 Million ] NewTimeSpace News: As of 10:28 on July 20, Bosera Szse Chinext Daily (2x) Leveraged Product (07234.HK) advanced 3.36%, with the latest price at HKD 9.220.
Tag： 07234.HKBosera Szse Chinext Daily (2x) Leveraged ProductETF
10:28
[ Chinaamc CSI 300 Index ETF (03188.HK) Rose 1.76% in Morning Trade, AUM at HKD 17.913 Billion ] NewTimeSpace News: As of 10:25 on July 20, Chinaamc CSI 300 Index ETF (03188.HK) advanced 1.76%, with the latest price at HKD 55.600.
Tag： Chinaamc CSI 300 Index ETFETF03188.HK
10:24
[ Chinaamc Hang Seng Tech Index Etf (03088.HK) Rose 3.49% in Morning Trade, Turnover at HKD 6.1013 Million ] NewTimeSpace News: As of 10:21 on July 20, Chinaamc Hang Seng Tech Index Etf (03088.HK) advanced 3.49%, with the latest price at HKD 6.085.
Tag： Chinaamc Hang Seng Tech Index EtfETF03088.HK
10:21
[ CSOP KOSPI 200 ETF (03121.HK) Rose 3.09% in Morning Trade, AUM at HKD 827 Million ] NewTimeSpace News: As of 10:18 on July 20, CSOP KOSPI 200 ETF (03121.HK) advanced 3.09%, with the latest price at HKD 5.840.
Tag： CSOP KOSPI 200 ETFETF03121.HK
10:18
[ E Fund (Hk) Solactive Asia Semiconductor Select Index Etf (03486.HK) Rose 1.85% in Morning Trade, Turnover at HKD 4.2539 Million ] NewTimeSpace News: As of 10:15 on July 20, E Fund (Hk) Solactive Asia Semiconductor Select Index Etf (03486.HK) advanced 1.85%, with the latest price at HKD 19.790.
Tag： 03486.HKETFE Fund (Hk) Solactive Asia Semiconductor Select Index Etf
10:15
[ iShares Core MSCI AC Asia ex Japan Index ETF (03010.HK) Rose 2.21% in Morning Trade, AUM at HKD 36.07 Billion ] NewTimeSpace News: As of 10:13 on July 20, iShares Core MSCI AC Asia ex Japan Index ETF (03010.HK) advanced 2.21%, with the latest price at HKD 84.980.
Tag： iShares Core MSCI AC Asia ex Japan Index ETF03010.HKETF
10:03
[ Global X China Semiconductor ETF (03191.HK) Rose 2.31% in Morning Trade, Latest Price at HKD 93.000 ] NewTimeSpace News: As of 09:58 on July 20, Global X China Semiconductor ETF (03191.HK) advanced 2.31%, with the latest price at HKD 93.000.
Tag： 03191.HKETFGlobal X China Semiconductor ETF
09:58
[ E Fund (HK) CSI Liquor Index ETF (03189.HK) Rose 5.06% in Morning Trade, Turnover at HKD 2.6414 Million ] NewTimeSpace News: As of 09:54 on July 20, E Fund (HK) CSI Liquor Index ETF (03189.HK) advanced 5.06%, with the latest price at HKD 1.162.
Tag： E Fund (HK) CSI Liquor Index ETFETF03189.HK
09:54
[ Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) Rose 4.08% in Morning Trade, Turnover at HKD 24.7138 Million ] NewTimeSpace News: As of 09:52 on July 20, Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) advanced 4.08%, with the latest price at HKD 9.705.
Tag： 03431.HKETFCsop Ftse Hk-Korea Tech+ Index ETF
09:52
[ Chinaamc Msci China A 50 Connect Etf (02839.HK) Rose 2.21% in Morning Trade, AUM at HKD 1.82 Billion ] NewTimeSpace News: As of 09:47 on July 20, Chinaamc Msci China A 50 Connect Etf (02839.HK) advanced 2.21%, with the latest price at HKD 32.340.
Tag： Chinaamc Msci China A 50 Connect EtfETF02839.HK
09:15
[ ZHONGJI INNOLIGHT: CSRC Completes Filing for Overseas Listing, Proposes Issuance of Up to 94.0044 Million H Shares ] NewTimeSpace News: ZHONGJI INNOLIGHT has obtained an overseas listing filing notice issued by the CSRC. The Company plans to issue no more than 94,004,350 overseas-listed ordinary shares for listing on the Main Board of HKEX.
Tag： Zhongji InnolightIPOFiling Notice for Overseas Issuance and ListingFull Circulation
08:57
[ YUEN KEE DUMPLING: CSRC Approves Filing for Overseas Listing & Full Circulation, Proposes Issuance of Up to 23.824 Million H Shares; 20 Shareholders to Convert 82.316 Million Domestic Shares to H Shares ] NewTimeSpace News: YUEN KEE DUMPLING has obtained filing approval from CSRC for its overseas listing and full circulation of domestic unlisted shares. The Group plans to issue a maximum of 23.824 million H Shares, while 20 shareholders intend to convert 82.316 million domestic shares to H Shares. The filing is valid for 12 months. CSRC does not provide substantive judgment or guarantee on the investment value of the enterprise.
Tag： YUEN KEE DUMPLINGIPOFull CirculationFiling Notice for Overseas Issuance and Listing
08:48
[ RELYEZ: Obtains CSRC Overseas Listing Filing Notice, Proposes Issuance of Up to 135 Million H Shares ] NewTimeSpace News: RELYEZ has obtained filing approval from CSRC for overseas listing. The Company proposes to issue no more than approximately 135 million H Shares for listing on HKEX Main Board. Meanwhile, domestic unlisted shares totalling 352 million held by 13 shareholders will be converted into H Shares for full circulation.
Tag： RelyEZ EnergySupplementary Materials for Overseas Issuance and Listing RegistrationFull CirculationIPO
08:23
[ CSTONE PHARMA-B (02616.HK): Clinical Data of CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Selected for ESMO 2026, Two Rapid Oral Presentations Scheduled ] NewTimeSpace News: CSTONE PHARMA-B (02616.HK) announced on 20 July that clinical data of its core asset CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, has been accepted by ESMO Congress 2026 for two rapid oral presentations covering Phase I/II trial results in advanced NSCLC and metastatic colorectal cancer patients. Updated full data will be unveiled at the Madrid conference held from 23 to 26 October 2026. The Company reminds investors of uncertainties in the clinical development and commercialization of CS2009.
Tag： CSTONE PHARMA-B02616.HKESMO 2026
08:15
[ IMPACT THERAP-B (07630.HK): Clinical Data of Senaparib, IMP1734 and IMP1707 Accepted for Poster Presentations at ESMO Congress 2026 ] NewTimeSpace News: IMPACT THERAP-B (07630.HK) announced on 20 July that clinical data of three pipeline assets, namely senaparib, IMP1734 and IMP1707, have been accepted as poster presentations for the ESMO Congress 2026. Senaparib has been approved in China for first-line maintenance therapy of advanced ovarian cancer and included in the national medical insurance catalogue, with its European MAA filed and accepted by EMA. IMP1734 and IMP1707 are next-generation selective PARP1 inhibitors.
Tag： IMPACT THERAP-B07630.HKposter presentation
08:08
[ JACOBIO-B (01167.HK): Pan-KRAS Inhibitor JAB-23E73 in Combination with Chemotherapy Completes First Patient Dosing in China for Phase Ib/III First-Line Treatment of KRAS-Mutant Pancreatic Cancer ] NewTimeSpace News: JACOBIO-B (01167.HK) announced on 20 July that its pan-KRAS inhibitor JAB-23E73 combined with nab-paclitaxel and gemcitabine completed first patient dosing in China for a Phase Ib/III clinical trial as first-line therapy for KRAS-mutant pancreatic cancer. Earlier Phase I data showed an ORR of 38.5% with favourable safety profile. AstraZeneca has obtained exclusive global rights (excluding mainland China), where the two parties co-develop and co-commercialise the candidate. The Company cautions uncertainties exist in drug development.
Tag： JACOBIO-B01167.HKClinical Trial
Previous1..274275 276277278..580     580 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments